Atara Biotherapeutics Inc
NASDAQ:ATRA
Atara Biotherapeutics Inc
NASDAQ:ATRA
Price:
0.6036 USD
Market Closed
Updated:
May 17, 2024
Atara Biotherapeutics Inc
Current Portion of Long-Term Debt
|
Atara Biotherapeutics Inc
Current Portion of Long-Term Debt Peer Comparison
Comparables:
ABBV
GILD
AMGN
VRTX
REGN
Competitive Current Portion of Long-Term Debt Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Current Portion of Long-Term Debt | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Atara Biotherapeutics Inc
NASDAQ:ATRA
|
Current Portion of Long-Term Debt
$945k
|
CAGR 3-Years
N/A
|
CAGR 5-Years
19%
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Current Portion of Long-Term Debt
$7.2B
|
CAGR 3-Years
-5%
|
CAGR 5-Years
35%
|
CAGR 10-Years
82%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Current Portion of Long-Term Debt
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Current Portion of Long-Term Debt
$4B
|
CAGR 3-Years
37%
|
CAGR 5-Years
1%
|
CAGR 10-Years
5%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Current Portion of Long-Term Debt
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Current Portion of Long-Term Debt
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
See Also
What is Atara Biotherapeutics Inc's Current Portion of Long-Term Debt?
Current Portion of Long-Term Debt
945k
USD
945k
USD
Based on the financial report for Mar 31, 2024, Atara Biotherapeutics Inc's Current Portion of Long-Term Debt amounts to 945k USD.
What is Atara Biotherapeutics Inc's Current Portion of Long-Term Debt growth rate?
Current Portion of Long-Term Debt CAGR 5Y
19%
19%
Over the last year, the Current Portion of Long-Term Debt growth was 18%.
You don't have any saved screeners yet
